• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2017 Fiscal Year Final Research Report

Intratumoral heterogeneity of lung cancer and its influence on the companion diagnostics

Research Project

  • PDF
Project/Area Number 15K08373
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Human pathology
Research InstitutionNational Cancer Center Japan

Principal Investigator

Motoi Noriko  国立研究開発法人国立がん研究センター, 中央病院, 医長 (70292878)

Co-Investigator(Renkei-kenkyūsha) ISHIKAWA Yuichi  がん研究会がん研究所, 病理部, 部長 (80222975)
OKUMURA Sakae  がん研究会がん研有明病院, 呼吸器外科, 部長 (40465935)
NISHIO Makoto  がん研究会がん研有明病院, 呼吸器内科, 部長 (00281593)
Project Period (FY) 2015-04-01 – 2018-03-31
KeywordsLung Cancer / Biomarker / Tumor heterogeneity / Companion diagnostic / PD-L1 / ALK / MET
Outline of Final Research Achievements

It is one of the urgent issue to establish an appropriate companion diagnostic system to proceed precision medicine in oncology, especially lung cancer in which many targetable genomic and immunological alteration have been explored. The aim of this study is to explore the mechanism of discordancy and inappropriate results in pathological companion diagnostics of lung cancer, especially focusing on its intratumoral heterogeneity. Our results indicated that the morphological heterogeneity was the sum of genomic and epigenomic alterations, and the fundamental driver oncogenic mutation (such as ALK) was retained through progression, then modified by the additional alterations. Of lung cancer with MET exon 14 skipping mutation, morphology and/or IHC based system had low power for screening. Our study suggested the importance of quality control of PD-L1 IHC as a biomarker of ICI therapy and needs for further technical innovation to reproducibility.

Free Research Field

Pathology

URL: 

Published: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi